Hormonal
Daily intake of 1-3 grams of n-3 omega fatty acids (EPA/DHA) reduces cardiovascular risk by lowering serum triglycerides and LDL cholesterol, and inhibiting platelet aggregation.
To support heart health, aim for 1-3 grams of EPA/DHA daily, preferably through fatty fish or high-quality supplements. This dosage has been shown to lower triglycerides and LDL cholesterol. If you have existing heart conditions, consult a doctor, as high doses may interact with medications.
According to Harris et al. (2003), of all known dietary factors, long-chain omega 3 fatty acids may be the most protective against death from coronary heart disease (CHD), by increasing the n-3 omega intake of an individual with coronary artery disease by approximately 1 g day)1... daily supplementations of 3 g in men and EPA containing soy phospholipid at 10% level in rat can decrease total serum cholesterol and LDL... whilst slightly increasing high density lipoprotein (Lox, 1990)
Why this rating
The paper cites multiple studies, meta-analyses, and clinical trials, though it notes some conflicting evidence regarding LDL increases in specific contexts.
Source
n‐3 Omega fatty acids: a review of current knowledge
Uğur Göğüş et al. · International Journal of Food Science & Technology · 2010
DOI 10.1111/j.1365-2621.2009.02151.x
More from this paper
- n-3 omega fatty acids reduce inflammation by inhibiting the production of pro-inflammatory eicosanoids (PGE2, TXA2, LTB4) and promoting anti-inflammatory eicosanoids (PGE1, PGI3, LTB5).Strong
- High doses of n-3 omega fatty acids (1.8 g/day) may accelerate heart rate and increase the risk of ventricular tachycardia or fibrillation in patients with existing ventricular arrhythmias.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →